Wednesday, June 4, 2008

ASCO e-News Published: Progress in Personalized Therapy: KRAS Status Predicts Response to First-line Cetuximab for Metastatic Colorectal Cancer

The American Society of Clinical Oncology's (ASCO) e-News was published and is available at http://view.exacttarget.com/?j=fe6215757261057d771c&m=ff2d16787160&ls=fde7127273610c7e771c777c&l=fe5b1574726503797c17&s=fdf2157972640d79751d7073&ju=fe1c15787d63027e731779.

It features:

Progress in Personalized Therapy: KRAS Status Predicts Response to First-line Cetuximab for Metastatic Colorectal Cancer

Zoledronic Acid Added to Endocrine Therapy Improves Outcome for Premenopausal Patients with Early Breast Cancer

International Trial Establishes Role of Cetuximab for Advanced EGFR-expressing NSCLC

Single Injection of Carboplatin Reported to be an Option for the Treatment of Stage I Seminoma

Trial Results Establish Clinical Benefit of RAD001 as Treatment for Advanced Renal Cell Carcinoma

Caution Urged in Prescribing Erythropoiesis-stimulating Agents

For Your Patients: News and Information from the 2008 ASCO Annual Meeting

No comments: